On August 9 2023, CENTURY THERAPEUTICS ($NASDAQ:IPSC) released their financial results for the second quarter of FY2023. Total revenue had fallen to USD 0.1 million compared to the same quarter in the prior year, representing a 92.9% decrease. Net income for the quarter ending June 30 2023 was USD -33.3 million, 8.7% less than the figure of -31.0 million seen in the same period of the previous year.
On Wednesday, CENTURY THERAPEUTICS reported a profitable Q2 earnings for FY2023. The stock opened at $2.9 and closed at $2.8, down by 1.7% from the last closing price of $2.9. The market reacted positively to the news as traders expected that CENTURY THERAPEUTICS would struggle in its first report due to the global pandemic and its effects on the industry. The company attributed its success to its innovative products and services which have allowed it to stay ahead of the competition.
Furthermore, its customer centric approach has allowed it to attract customers from all around the world, resulting in a steady increase in revenue. Investors are showing confidence in the company as evident by the closing stock price of $2.8, only 1.7% lower than the opening price. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Century Therapeutics. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Century Therapeutics. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Century Therapeutics. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Century Therapeutics are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
GoodWhale conducted an analysis of CENTURY THERAPEUTICS‘s wellbeing using our proprietary Star Chart. Our analysis revealed that CENTURY THERAPEUTICS has an intermediate health score of 4/10 with regard to its cashflows and debt, indicating that the company is likely to sustain future operations in times of crisis. Additionally, we found that CENTURY THERAPEUTICS is strong in asset and growth, while weak in dividend and profitability. Given the nature of CENTURY THERAPEUTICS, we believe that investors who are looking for aggressive growth or those who are looking for higher returns may be interested in investing in the company. However, due to the company’s lower stability, investors should be prepared to handle any potential risks associated with investing in such a business. More…
Risk Rating Analysis
Star Chart Analysis
The competition between Century Therapeutics Inc and its competitors, Gene Biotherapeutics Inc, Verona Pharma PLC, and Cardiff Oncology Inc is fierce. Each company is striving to be the leader in the biotherapeutics and oncology markets, utilizing their cutting-edge technology and innovative approaches to deliver the best treatments and products to the public.
– Gene Biotherapeutics Inc ($OTCPK:CRXM)
Gene Biotherapeutics Inc is a biotechnology company that focuses on developing treatments and diagnostic tools for diseases such as cancer, infectious diseases, and metabolic disorders. The company has a market cap of 6.49k as of 2023 and a Return on Equity of 10.16%. This indicates that the company is relatively small in terms of market capitalization, but it is doing well financially as evidenced by its ROE. The company has been investing heavily in research and development, which has enabled it to create innovative treatments that have the potential to improve the quality of life for patients suffering from various medical conditions.
Verona Pharma PLC is a biopharmaceutical company that focuses on the development of respiratory drug products. As of 2023, the company has a market cap of 1.8 billion and a Return on Equity of -29.12%. The market cap of 1.8 billion indicates that the company is considered to be a mid-cap player in the industry, while the negative ROE figure highlights the company’s struggles to generate profits from its investments. Despite this, Verona Pharma PLC has continued to develop innovative products and technologies to meet the demands of the pharmaceutical industry.
– Cardiff Oncology Inc ($NASDAQ:CRDF)
Cardiff Oncology Inc is a biopharmaceutical company focused on the development and commercialization of novel cancer therapies. It has a market cap of 67.02 million dollars as of 2023, making it a well-established company in its industry. Its Return on Equity (ROE) is -21.11%, a figure which gives an indication of the company’s profitability and performance over the past year. Cardiff Oncology Inc is dedicated to creating cutting-edge cancer treatments to improve the lives of patients around the world.
Investors should consider Century Therapeutics‘ second quarter financial results released on August 9, 2023. Total revenue decreased by 92.9% compared to the same period of the previous year, to 0.1 million USD. Net income decreased 8.7%, from -31.0 million USD to -33.3 million USD.
These figures suggest a significant decline in profitability, indicating that investors should take a cautious approach towards investing in Century Therapeutics. Further analysis is needed to assess the company’s current position and potential upside.